Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASHISH C BHATIA

Allopathic & Osteopathic Physicians Dermatology Procedural Dermatology

NPI
1073595690
CMS profile
48239
Location
ITASCA, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$26,015.03

79 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $19,200.00 7
Consulting Fee $4,172.50 2
Food and Beverage $1,671.38 63
Travel and Lodging $971.15 7

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASHISH C BHATIA

NPI 1073595690 · CMS profile ID 48239

Allopathic & Osteopathic Physicians / Dermatology / Procedural Dermatology

ITASCA, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073595690?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASHISH C BHATIA, NPI 1073595690, CMS profile ID 48239. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073595690?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ASHISH C BHATIA, NPI 1073595690, CMS profile ID 48239. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073595690?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ASHISH C BHATIA, NPI 1073595690, CMS profile ID 48239, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–79 of 79 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1073595690?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

79 matching records · $26,015.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 79 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–79 of 79.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
VYNE Pharmaceuticals Inc. $1,800.0005/27/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830825923 CMS
VYNE Pharmaceuticals Inc. $3,600.0005/27/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830826627 CMS
Medline Industries, Inc. $1,000.0005/21/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849643765 CMS
Medline Industries, Inc. $132.1605/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849643767 CMS
VYNE Pharmaceuticals Inc. $36.7705/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830825917 CMS
VYNE Pharmaceuticals Inc. $102.9605/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830826803 CMS
LEO Pharma Inc. $66.9305/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842144203 CMS
Genentech USA, Inc. $19.3605/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835890569 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $13.7305/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849547265 CMS
Janssen Biotech, Inc. $20.7104/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788998653 CMS
VYNE Pharmaceuticals Inc. $3,600.0004/22/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830824085 CMS
DERMIRA, INC. $17.7604/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 764402708 CMS
ORGANOGENESIS INC. $23.0604/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835467231 CMS
AbbVie Inc. $26.4304/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794063277 CMS
VYNE Pharmaceuticals Inc. $14.3904/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830825921 CMS
VYNE Pharmaceuticals Inc. $122.0804/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830825927 CMS
Janssen Biotech, Inc. $15.5104/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788998683 CMS
VYNE Pharmaceuticals Inc. $3,600.0003/25/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830824089 CMS
VYNE Pharmaceuticals Inc. $102.9603/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830825929 CMS
VYNE Pharmaceuticals Inc. $71.9703/18/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830826807 CMS
AbbVie Inc. $6.9503/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794063273 CMS
Amgen Inc. $16.8003/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826298543 CMS
VYNE Pharmaceuticals Inc. $1,800.0003/04/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830816067 CMS
VYNE Pharmaceuticals Inc. $53.0002/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830826805 CMS
AbbVie Inc. $19.5102/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794063269 CMS
Medline Industries, Inc. $398.3902/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849643777 CMS
Medline Industries, Inc. $148.2902/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849643779 CMS
PFIZER INC. $18.2301/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832622369 CMS
Biofrontera Inc. $11.1501/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 785321923 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $48,002.59 141
PY2020 $32,847.82 56
PY2021 $26,015.03 79
PY2022 $4,980.33 43
PY2023 $80,524.79 80
PY2024 $105,361.56 137
PY2025 $136,598.48 196

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,917.70 12
PY2025 Principal investigator $72,215.05 9
PY2024 Recipient $2,386.50 1
PY2022 Recipient $70,985.00 3
PY2021 Principal investigator $4,578.53 3
PY2020 Recipient $18,800.00 1
PY2020 Principal investigator $124,081.71 11
PY2019 Recipient $20,980.89 10
PY2019 Principal investigator $5,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,447.65 11/14/2025 Non-covered Recipient Entity
OAK DERMATOLOGY LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184260953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $807.82 10/03/2025 Non-covered Recipient Entity
OAK DERMATOLOGY LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184244807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,734.90 09/18/2025 Non-covered Recipient Entity
OAK DERMATOLOGY LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184240674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,402.02 09/11/2025 Non-covered Recipient Entity
OAK DERMATOLOGY LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184236089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,880.78 09/04/2025 Non-covered Recipient Entity
OAK DERMATOLOGY LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184235293
Principal investigator 1 Eli Lilly and Company $1,478.10 08/26/2025 Non-covered Recipient Entity
OAK DERMATOLOGY
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187890158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,402.02 08/26/2025 Non-covered Recipient Entity
OAK DERMATOLOGY LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184230463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,729.76 08/21/2025 Non-covered Recipient Entity
OAK DERMATOLOGY LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184229797
Recipient Eli Lilly and Company $1,084.80 03/25/2025 Covered Recipient Physician EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187873825
Recipient Regeneron Pharmaceuticals, Inc. $268.03 03/10/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115673
Recipient Regeneron Pharmaceuticals, Inc. $64.50 02/25/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115669
Recipient Regeneron Pharmaceuticals, Inc. $59.50 02/25/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115671
Principal investigator 1 Eli Lilly and Company $56,332.00 02/18/2025 Non-covered Recipient Entity
OAK DERMATOLOGY
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187886848
Recipient Regeneron Pharmaceuticals, Inc. $162.74 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115657
Recipient Regeneron Pharmaceuticals, Inc. $446.00 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115659
Recipient Regeneron Pharmaceuticals, Inc. $68.89 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115661
Recipient Regeneron Pharmaceuticals, Inc. $30.01 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115663
Recipient Regeneron Pharmaceuticals, Inc. $96.17 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115665
Recipient Regeneron Pharmaceuticals, Inc. $62.01 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115667
Recipient Regeneron Pharmaceuticals, Inc. $178.09 02/06/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115655
Recipient Regeneron Pharmaceuticals, Inc. $396.96 01/15/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115653